scholarly journals Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women

2013 ◽  
Vol 21 (2) ◽  
pp. 263-273 ◽  
Author(s):  
Vanessa W Lim ◽  
Jun Li ◽  
Yinhan Gong ◽  
Aizhen Jin ◽  
Jian-Min Yuan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Postmenopausal Breast Cancer ◽  
Positive Association ◽  
Serum Levels ◽  
Population Based ◽  
Health Study ◽  
Baseline Serum

The estrogen levels of Asian women are different from those of Western women, and this could affect estrogen receptor (ER) bioactivity and breast cancer risk. We conducted a case–control study in 169 postmenopausal breast cancer cases and 426 matched controls nested within a population-based prospective cohort study, the Singapore Chinese Health Study, to evaluate the serum levels of estrogens and their receptor (ERα and ERβ)-mediated estrogenic activities in relation to breast cancer risk. Breast cancer cases had higher levels of estrogens and ER-mediated bioactivities in baseline serum than the controls. Compared with those in the lowest quartile, women in the highest quartile for estrone (E1) or ERα-mediated bioactivity had increased breast cancer risk. After additional adjustment for ERβ bioactivity, free estradiol, and E1levels, serum ERα-mediated bioactivity remained associated with increased breast cancer risk. Compared with those in the lowest quartile, women in the highest quartile for ERα-mediated bioactivity had an odds ratio of 2.39 (95% CI=1.17–4.88;Pfor trend=0.016). Conversely, the positive association between E1and cancer risk became null after adjustment for ERα-mediated bioactivity, suggesting that the effect of E1could be mediated through ERα. Factor(s) contributing to increased ERα-mediated estrogenic bioactivity in serum and its role as a predictor for breast cancer risk need to be validated in future studies.

scholarly journals Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: A prospective nested case-control study

2021 ◽  
Author(s):  
Ylva Bengtsson ◽  
Malte Sandsveden ◽  
Signe Borgquist ◽  
Jonas Manjer
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Dietary Intake ◽  
Serum Zinc ◽  
Serum Levels ◽  
Population Based ◽  
Zinc Intake ◽  
Baseline Serum ◽  
Incident Cases

Abstract Purpose Zinc has been suggested to be protective against breast cancer, but the evidence remains inconclusive. One reason for inconsistent findings in previous studies may be that zinc only influences the risk of developing certain subtypes of breast cancer. Our study is the first study assessing zinc levels in relation to the risk of different breast cancer subgroups, defined by their tumor characteristics. In addition, we analyze serum zinc as a marker of dietary intake. Methods The Malmö Diet and Cancer Study is a population-based cohort study that took place 1991-1996 in Malmö, Sweden. Until end of follow-up, 31 December 2013, 1186 incident cases were identified and matched to an equal number of controls. Odds ratios (ORs) for breast cancer, and having a certain tumor characteristic, were estimated in quartiles of baseline serum zinc and zinc intake and adjusted for potential confounders. Results No associations were found between zinc, measured in serum or diet pre-diagnostically, and breast cancer risk. The adjusted OR for breast cancer in serum zinc Q4 compared to Q1 was 1.09 (0.85-1.41) and in zinc intake Q4 versus Q1 was 0.97 (0.77-1.23). Moreover, there were no clear associations between zinc and any breast cancer characteristics. The kappa value, 0.025 (P=0.022), showed poor agreement between serum zinc and zinc intake. Conclusion Our findings indicate that there is no clear association between zinc and overall breast cancer risk or risk of different breast cancer subgroups. Finally, our results suggest that serum zinc is a poor marker of zinc intake.

scholarly journals Serum zinc and dietary intake of zinc in relation to risk of different breast cancer subgroups and serum levels as a marker of intake: a prospective nested case-control study

2021 ◽  
Author(s):  
Ylva Bengtsson ◽  
Malte Sandsveden ◽  
Signe Borgquist ◽  
Jonas Manjer
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Dietary Intake ◽  
Serum Zinc ◽  
Serum Levels ◽  
Population Based ◽  
Zinc Intake ◽  
Baseline Serum ◽  
Incident Cases

Abstract Purpose Zinc has been suggested to be protective against breast cancer, but the evidence remains inconclusive. One reason for inconsistent findings in previous studies may be that zinc only influences the risk of developing certain subtypes of breast cancer. Our study is the first study assessing zinc levels in relation to the risk of different breast cancer subgroups, defined by their tumor characteristics. In addition, we analyze serum zinc as a marker of dietary intake. Methods The Malmö Diet and Cancer Study is a population-based cohort study that took place 1991–1996 in Malmö, Sweden. Until end of follow-up, 31 December 2013, 1186 incident cases were identified and matched to an equal number of controls. Odds ratios (ORs) for breast cancer, and having a certain tumor characteristic, were estimated in quartiles of baseline serum zinc and zinc intake and adjusted for potential confounders. Results No associations were found between zinc, measured in serum or diet pre-diagnostically, and breast cancer risk. The adjusted OR for breast cancer in serum zinc Q4 compared to Q1 was 1.09 (0.85–1.41) and in zinc intake Q4 versus Q1 was 0.97 (0.77–1.23). Moreover, there were no clear associations between zinc and any breast cancer characteristics. The kappa value, 0.025 (P = 0.022), showed poor agreement between serum zinc and zinc intake. Conclusion Our findings indicate that there is no clear association between zinc and overall breast cancer risk or risk of different breast cancer subgroups. Finally, our results suggest that serum zinc is a poor marker of zinc intake.

scholarly journals A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3303
Author(s):  
Debora Macis ◽  
Valentina Aristarco ◽  
Harriet Johansson ◽  
Aliana Guerrieri-Gonzaga ◽  
Sara Raimondi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cox Model ◽  
Disease Free Survival ◽  
Postmenopausal Breast Cancer ◽  
Enzyme Linked Immunosorbent Assay ◽  
Baseline Serum ◽  
Free Survival ◽  
Disease Free

Adiponectin and leptin are adipokines secreted by the adipose tissue that are associated with several chronic diseases including cancer. We aimed to compare the immunoassay platform ELLA with an enzyme-linked immunosorbent assay (ELISA) kit and to assess whether the results of the association analyses with breast cancer risk were dependent on the assay used. We measured adiponectin and leptin with ELLA and ELISA on baseline serum samples of 116 Italian postmenopausal women enrolled in two international breast cancer prevention trials. Results were compared with Deming, Passing–Bablok regression and Bland–Altman plots. Disease-free survival was analyzed with the Cox model. There was a good correlation between the methods for adiponectin and leptin (r > 0.96). We found an increased breast cancer risk for very low adiponectin levels (HR for ELLA = 3.75; 95% CI: 1.37;10.25, p = 0.01), whereas no significant association was found for leptin levels. The disease-free survival curves were almost identical for values obtained with the two methods, for both biomarkers. The ELLA platform showed a good concordance with ELISA for adiponectin and leptin measurements. Our results support the association of very low adiponectin levels with postmenopausal breast cancer risk, irrespective of the method used. The ELLA platform is a time-saving system with high reproducibility, therefore we recommend its use for biomarker assessment.

scholarly journals Adiposity and estrogen receptor‐positive, postmenopausal breast cancer risk: Quantification of the mediating effects of fasting insulin and free estradiol

2019 ◽  
Vol 146 (6) ◽  
pp. 1541-1552 ◽  
Author(s):  
S. Ghazaleh Dashti ◽  
Julie A. Simpson ◽  
Amalia Karahalios ◽  
Vivian Viallon ◽  
Margarita Moreno‐Betancur ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Postmenopausal Breast Cancer ◽  
Fasting Insulin ◽  
Mediating Effects ◽  
Risk Quantification ◽  
Estrogen Receptor Positive ◽  
Free Estradiol

scholarly journals Intensity and timing of physical activity in relation to postmenopausal breast cancer risk: the prospective NIH-AARP Diet and Health Study

BMC Cancer ◽  
2009 ◽  
Vol 9 (1) ◽  
Author(s):  
Tricia M Peters ◽  
Steven C Moore ◽  
Gretchen L Gierach ◽  
Nicholas J Wareham ◽  
Ulf Ekelund ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Postmenopausal Breast Cancer ◽  
Health Study ◽  
Postmenopausal Breast Cancer Risk

scholarly journals Estrogen receptor α polymorphisms and postmenopausal breast cancer risk

2007 ◽  
Vol 107 (3) ◽  
pp. 415-419 ◽  
Author(s):  
A. M. González-Zuloeta Ladd ◽  
A. Arias Vásquez ◽  
F. Rivadeneira ◽  
C. Siemes ◽  
A. Hofman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Postmenopausal Breast Cancer ◽  
Estrogen Receptor Α ◽  
Postmenopausal Breast Cancer Risk

scholarly journals Branched chain amino acids and risk of breast cancer

2020 ◽  
Author(s):  
Oana A Zeleznik ◽  
Raji Balasubramanian ◽  
Yumeng Ren ◽  
Deirdre K Tobias ◽  
Bernard Rosner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Menopausal Status ◽  
External Validation ◽  
Postmenopausal Breast Cancer ◽  
Health Study ◽  
Blood Draw ◽  
Branched Chain

Circulating branched chain amino acid (BCAA) levels reflect metabolic health and dietary intake. However, associations with breast cancer are unclear. We evaluated circulating BCAA levels and breast cancer risk within the Nurses' Health Study (NHS) and NHSII (1,997 cases, 1,997 matched controls). 592 NHS women donated two blood samples 10 years apart. We estimate odds ratios (OR) and 95% confidence intervals (CI) of breast cancer risk in multivariable logistic regression models. We conducted an external validation with secondary analyses in the Women's Health Study (WHS; 1,297 cases). Among NHSII participants (predominantly premenopausal at blood collection), elevated circulating BCAA levels were associated with lower breast cancer risk (e.g., isoleucine highest vs. lowest quartile, multivariable OR(95% CI)=0.86(0.65-1.13), p-trend=0.20), with significant linear trends among fasting samples (e.g., isoleucine OR(95% CI)=0.74(0.53-1.05), p-trend=0.05). In contrast, among postmenopausal women, proximate measures (<10y from blood draw) were associated with increased breast cancer risk (e.g., isoleucine OR(95% CI)=1.63(1.12-2.39), p-trend=0.01), with stronger associations among fasting samples (OR(95% CI)=1.73(1.15-2.61), p-trend=0.01). Distant measures (10-20y since blood draw) were not associated with risk. In the WHS, a positive association was observed for distant measures of leucine among postmenopausal women: OR(95% CI)=1.31(0.97-1.75), p-trend=0.05. Although elevated circulating BCAA levels were associated with lower breast cancer risk among premenopausal NHSII women and higher risk of postmenopausal breast cancer in NHS (<10y from blood draw), independent of established risk factors, including adiposity, results were not validated in WHS. Additional studies are needed to understand the complex relationship between BCAAs, menopausal status, and risk of breast cancer.

scholarly journals Physical Activity and Postmenopausal Breast Cancer Risk in the NIH-AARP Diet and Health Study

2009 ◽  
Vol 18 (1) ◽  
pp. 289-296 ◽  
Author(s):  
Tricia M. Peters ◽  
Arthur Schatzkin ◽  
Gretchen L. Gierach ◽  
Steven C. Moore ◽  
James V. Lacey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Postmenopausal Breast Cancer ◽  
Health Study ◽  
Postmenopausal Breast Cancer Risk

scholarly journals Association of Interactions Between Mammographic Density Phenotypes and Established Risk Factors With Breast Cancer Risk, by Tumor Subtype and Menopausal Status

2020 ◽  
Vol 190 (1) ◽  
pp. 44-58
Author(s):  
Hongjie Chen ◽  
Lusine Yaghjyan ◽  
Christopher Li ◽  
Ulrike Peters ◽  
Bernard Rosner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Estrogen Receptor ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Mammographic Density ◽  
Estrogen Receptor Status ◽  
Health Study ◽  
Receptor Status ◽  
Dense Tissue

Abstract Previous studies suggest that the association between mammographic density (MD) and breast cancer risk might be modified by other breast cancer risk factors. In this study, we assessed multiplicative interactions between MD measures and established risk factors on the risk of invasive breast cancer overall and according to menopausal and estrogen receptor status. We used data on 2,137 cases and 4,346 controls from a nested case-control study within the Nurses’ Health Study (1976–2004) and Nurses’ Health Study II (1989–2007), whose data on percent mammographic density (PMD) and absolute area of dense tissue and nondense tissue (NDA) were available. No interaction remained statistically significant after adjusting for number of comparisons. For breast cancer overall, we observed nominally significant interactions (P &lt; 0.05) between nulliparity and PMD/NDA, age at menarche and area of dense tissue, and body mass index and NDA. Individual nominally significant interactions across MD measures and risk factors were also observed in analyses stratified by either menopausal or estrogen receptor status. Our findings help provide further insights into potential mechanisms underlying the association between MD and breast cancer.

Sign in / Sign up

Export Citation Format

Share Document